{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:00:53Z","timestamp":1793962853224,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.metabol.2023.155642","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T20:40:46Z","timestamp":1687812046000},"page":"155642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States"],"prefix":"10.1016","volume":"146","author":[{"given":"Pegah","family":"Golabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameeta","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Al Shabeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine E.","family":"Eberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagashree","family":"GunduRao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2023.155642_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0010","doi-asserted-by":"crossref","DOI":"10.1111\/apt.17158","article-title":"Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world","author":"Henry","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2023.155642_bb0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/hep4.1915","article-title":"Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States scientific registry of transplant recipients","volume":"6","author":"Stepanova","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2023.155642_bb0020","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0048","article-title":"Nonalcoholic steatohepatitis: global impact and clinical consequences","author":"Kabarra","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.metabol.2023.155642_bb0025","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","article-title":"Nonalcoholic fatty liver disease: review of management for primary care providers","volume":"97","author":"Basu","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.metabol.2023.155642_bb0030","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155642_bb0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0040","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0050","first-page":"21","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","author":"Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.metabol.2023.155642_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2023.155642_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.14797\/mdcj-14-4-289","article-title":"Prediabetes: why should we care?","volume":"14","author":"Zand","year":"2018","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.metabol.2023.155642_bb0070","unstructured":"National Center for Health Statistics (NCHS). Plan and operation of the third national health and nutrition examination survey 1988\u201394. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Center for Disease Control and Prevention n.d. http:\/\/www.cdc.gov\/nhcs\/data\/series\/sr_02\/sr02_113.pdf (accessed August 16, 2016)."},{"key":"10.1016\/j.metabol.2023.155642_bb0075","unstructured":"Third National Health and Nutrition Examination Survey: Gallbladder Ultrasonography Procedure Manual, September 1988 n.d. https:\/\/www.cdc.gov\/nchs\/data\/nhanes\/nhanes3\/cdrom\/nchs\/manuals\/gallblad.pdf (accessed July 14, 2021)."},{"key":"10.1016\/j.metabol.2023.155642_bb0080","unstructured":"National Center for Health Statistics. National Health and nutrition examination survey: procedure manual, hepatic steatosis (Nov 2010), Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention [Internet]. Center for Disease Control and Prevention. Center for Disease Control and Prevention 2014. https:\/\/www.cdc.gov\/nchs\/data\/nhanes\/nhanes3\/hepatic_steatosis_ultrasound_procedures_manual.pdf. (accessed July 14, 2021)."},{"key":"10.1016\/j.metabol.2023.155642_bb0085","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apt.15580","article-title":"The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease","volume":"51","author":"Paik","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2023.155642_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.13012","article-title":"Fatty liver indices in the multiethnic United States National Health and nutrition examination survey","volume":"41","author":"Ruhl","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2023.155642_bb0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2023.155642_bb0105","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/liv.15437","article-title":"The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018","volume":"42","author":"Younossi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2023.155642_bb0110","unstructured":"Grundy SM, Brewer HB., Cleeman JI, Smith SC Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association \u2026. circulation n.d."},{"key":"10.1016\/j.metabol.2023.155642_bb0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13131","article-title":"National trends in American Heart Association revised Life\u2019s simple 7 metrics associated with risk of mortality among US adults","volume":"2","author":"Han","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2023.155642_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.2061","article-title":"Sarcopenia, healthy living, and mortality in patients with chronic liver diseases","author":"Van Dongen","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2023.155642_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2023.155642_bb0130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease","volume":"39","author":"Paik","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2023.155642_bb0135","series-title":"A practical guide, SAS Institute, Cary, NC, SAS Institute, Inc. vol. iii, 292 p.\u202f: ill. . Cary, NC\u202f: SAS Institute, c1995 (2001 printing)","author":"Allison","year":"1995"},{"key":"10.1016\/j.metabol.2023.155642_bb0140","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2023.155642_bb0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155642_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.metabol.2023.155642_bb0155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0160","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0180","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2023.155642_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155642_bb0190","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity"},{"key":"10.1016\/j.metabol.2023.155642_bb0195","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0200","series-title":"Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and hepatic fibrosis among patients with prediabetes. Digestive disease week, Chicago, IL, May 7\u20139","author":"Golabi","year":"2023"},{"key":"10.1016\/j.metabol.2023.155642_bb0205","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2337\/dc11-1849","article-title":"Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)","volume":"35","author":"Ortiz-Lopez","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155642_bb0210","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.dsx.2019.07.060","article-title":"Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes","volume":"13","author":"Rajput","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.metabol.2023.155642_bb0215","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.metabol.2023.155642_bb0220","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.metabol.2023.155642_bb0225","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2023.155642_bb0230","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2174\/1381612826666200128094231","article-title":"Causes of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD)","volume":"26","author":"Johnston","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.metabol.2023.155642_bb0235","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220612","article-title":"Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis","volume":"14","author":"Wong","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2023.155642_bb0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3350\/cmh.2022.0096","article-title":"The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease","volume":"28","author":"Ng","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","article-title":"Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus","volume":"76","author":"Mallet","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0255","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission","volume":"41","author":"Wild","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2023.155642_bb0260","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155642_bb0265","first-page":"12","article-title":"Combined C-reactive protein and novel inflammatory parameters as a predictor in cancer-what can we learn from the hematological experience?","author":"Bruserud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.metabol.2023.155642_bb0270","doi-asserted-by":"crossref","first-page":"1012887","DOI":"10.3389\/fphys.2022.1012887","article-title":"Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD","volume":"13","author":"Huang","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2023.155642_bb0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2023.155642_bb0280","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155642_bb0285","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155642_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154874","article-title":"Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes","volume":"124","author":"Li","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2023.155642_bb0295","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2023.155642_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:37:20Z","timestamp":1736365040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523002469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":60,"alternative-id":["S0026049523002469"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155642","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155642"}}